Search
Tilbroquinol
go.drugbank.com/drugs/DB13222ApprovedIn Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
Satraplatin
go.drugbank.com/drugs/DB04996InvestigationalAs an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Apronalide
go.drugbank.com/drugs/DB13221ApprovedApronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalRimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell...
Borage oil
go.drugbank.com/drugs/DB11238ApprovedBorage oil may be found in foods or in skin care products. … Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although
Categories: Complex MixturesCLX-0921
go.drugbank.com/drugs/DB05854ExperimentalCLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones.
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).